SE9804614L - - Google Patents

Info

Publication number
SE9804614L
SE9804614L SE9804614A SE9804614A SE9804614L SE 9804614 L SE9804614 L SE 9804614L SE 9804614 A SE9804614 A SE 9804614A SE 9804614 A SE9804614 A SE 9804614A SE 9804614 L SE9804614 L SE 9804614L
Authority
SE
Sweden
Prior art keywords
relates
peptides
amino acids
food
inflammations
Prior art date
Application number
SE9804614A
Other languages
English (en)
Other versions
SE9804614D0 (sv
SE9804614A0 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of SE9804614L publication Critical patent/SE9804614L/xx
Priority claimed from SE9802441A external-priority patent/SE9802441D0/xx
Priority claimed from SE9802562A external-priority patent/SE9802562D0/xx
Application filed filed Critical
Priority to SE9804614A priority Critical patent/SE9804614A0/sv
Publication of SE9804614D0 publication Critical patent/SE9804614D0/xx
Priority to AT99935241T priority patent/ATE381578T1/de
Priority to US09/743,107 priority patent/US7253143B1/en
Priority to PT99935241T priority patent/PT1095061E/pt
Priority to JP2000558131A priority patent/JP4488622B2/ja
Priority to DE69937798T priority patent/DE69937798T2/de
Priority to NZ509622A priority patent/NZ509622A/en
Priority to CA2333306A priority patent/CA2333306C/en
Priority to DK99935241T priority patent/DK1095061T3/da
Priority to PCT/SE1999/001230 priority patent/WO2000001730A1/en
Priority to EP99935241A priority patent/EP1095061B1/de
Priority to AU50760/99A priority patent/AU752640B2/en
Priority to HK01107436.6A priority patent/HK1036630B/en
Priority to ES99935241T priority patent/ES2299253T3/es
Publication of SE9804614A0 publication Critical patent/SE9804614A0/sv
Priority to US11/819,901 priority patent/US7803757B2/en
Priority to CY20081100292T priority patent/CY1108049T1/el
Priority to JP2009283513A priority patent/JP2010090162A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00—Working-up of proteins for foodstuffs
    • A23J3/04—Animal proteins
    • A23J3/08—Dairy proteins
    • A23L1/3053—
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
SE9804614A 1998-07-06 1998-12-29 New peptides and use thereof SE9804614A0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
SE9804614A SE9804614A0 (en) 1998-07-06 1998-12-29 New peptides and use thereof
EP99935241A EP1095061B1 (de) 1998-07-06 1999-07-06 Peptide, basierend auf der sequenz des menschlichen lactoferrins und ihre anwendung
AU50760/99A AU752640B2 (en) 1998-07-06 1999-07-06 Peptides based on the sequence of human lactoferrin and their use
US09/743,107 US7253143B1 (en) 1998-07-06 1999-07-06 Peptides based on the sequence of human lactoferrin and their use
ES99935241T ES2299253T3 (es) 1998-07-06 1999-07-06 Peptidos basados en la secuencia de la lactoferrina humana y sus usos,.
DE69937798T DE69937798T2 (de) 1998-07-06 1999-07-06 Peptide, basierend auf der sequenz des menschlichen lactoferrins und ihre anwendung
HK01107436.6A HK1036630B (en) 1998-07-06 1999-07-06 Peptides based on the sequence of human lactoferrin and their use
PT99935241T PT1095061E (pt) 1998-07-06 1999-07-06 Péptidos baseados na sequência da lactoferrina humana e sua utilização
JP2000558131A JP4488622B2 (ja) 1998-07-06 1999-07-06 人ラクトフェリンの配列に基づくペプチドおよびその使用
AT99935241T ATE381578T1 (de) 1998-07-06 1999-07-06 Peptide, basierend auf der sequenz des menschlichen lactoferrins und ihre anwendung
NZ509622A NZ509622A (en) 1998-07-06 1999-07-06 Peptides based on the sequence of human lactoferrin and their use
CA2333306A CA2333306C (en) 1998-07-06 1999-07-06 Peptides based on the sequence of human lactoferrin and their use
DK99935241T DK1095061T3 (da) 1998-07-06 1999-07-06 Peptider baseret på sekvensen af humant lactoferring og deres anvendelse
PCT/SE1999/001230 WO2000001730A1 (en) 1998-07-06 1999-07-06 Peptides based on the sequence of human lactoferrin and their use
US11/819,901 US7803757B2 (en) 1998-07-06 2007-06-29 Peptides based on the sequence of human lactoferrin and their use
CY20081100292T CY1108049T1 (el) 1998-07-06 2008-03-14 Πεπτιδια με βαση την αλληλουχια της ανθρωπινης λακτοφερρινης και χρηση τους
JP2009283513A JP2010090162A (ja) 1998-07-06 2009-12-14 人ラクトフェリンの配列に基づくペプチドおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9802441A SE9802441D0 (sv) 1998-07-06 1998-07-06 New peptides and use thereof
SE9802562A SE9802562D0 (sv) 1998-07-17 1998-07-17 New peptides and use thereof
SE9804614A SE9804614A0 (en) 1998-07-06 1998-12-29 New peptides and use thereof

Publications (3)

Publication Number Publication Date
SE9804614L true SE9804614L (de) 1900-01-01
SE9804614D0 SE9804614D0 (sv) 1998-12-29
SE9804614A0 SE9804614A0 (en) 2000-01-07

Family

ID=27355931

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9804614A SE9804614A0 (en) 1998-07-06 1998-12-29 New peptides and use thereof

Country Status (14)

Country Link
US (2) US7253143B1 (de)
EP (1) EP1095061B1 (de)
JP (2) JP4488622B2 (de)
AT (1) ATE381578T1 (de)
AU (1) AU752640B2 (de)
CA (1) CA2333306C (de)
CY (1) CY1108049T1 (de)
DE (1) DE69937798T2 (de)
DK (1) DK1095061T3 (de)
ES (1) ES2299253T3 (de)
NZ (1) NZ509622A (de)
PT (1) PT1095061E (de)
SE (1) SE9804614A0 (de)
WO (1) WO2000001730A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9804614A0 (en) * 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
SE0200598D0 (sv) * 2002-02-27 2002-02-27 A & Science Invest Ab Pharmaceutical composition and method for treatment or prevention of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences
US7323443B2 (en) * 2002-12-12 2008-01-29 Agennix Inc. Lactoferrin in the reduction of pain
US8193310B2 (en) 2004-03-19 2012-06-05 The University Of Queensland Alpha helical mimics, their uses and methods for their production
WO2006047744A2 (en) 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
DE602006020617D1 (de) * 2005-12-30 2011-04-21 Evonik Roehm Gmbh Lactoferrin-peptide, geeignet als in die zelle eindringende peptide
EP2078529B1 (de) * 2006-07-10 2014-12-10 PBA3 Biomed GmbH Antimikrobielle Peptide
EP2114989B1 (de) * 2007-01-16 2016-04-06 Rutgers, the State University of New Jersey Natürliche polypeptide für mundhygiene
EP2050461A1 (de) * 2007-10-19 2009-04-22 PharmaSurgics in Sweden AB Peptide basierend auf der menschlichen Lactoferrinsequenz und ihre Verwendung
EP2060586A1 (de) * 2007-11-14 2009-05-20 PharmaSurgics in Sweden AB Neue synthetische Arginin-substituierte Peptide und ihre Verwendung
EP2300036B1 (de) 2008-06-09 2017-04-05 Palatin Technologies, Inc. Melanocortin-rezeptor-spezifische peptide zur behandlung von sexueller dysfunktion
ES2400466T3 (es) 2009-01-13 2013-04-10 Pergamum Ab Composiciones que contienen ácido hialurónico para el tratamiento de heridas, cicatrices y la formación de adherencias postquirúrgicas
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
AU2010321738B2 (en) 2009-11-23 2016-07-14 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
EP2504351A4 (de) 2009-11-23 2013-10-30 Palatin Technologies Inc Melanocortin-1-rezeptor-spezifische lineare peptide
JP5177901B2 (ja) * 2009-12-02 2013-04-10 株式会社明治 栄養組成物
CN101891885B (zh) * 2010-08-18 2012-12-12 中国科学院长春应用化学研究所 聚丝氨酸酯及其制备方法
EP2481751A1 (de) 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Humanem Lactoferrin abgeleitete Peptide
US20140255409A1 (en) * 2011-10-28 2014-09-11 Glycorex Transplantation Ab Method for extracorporeal elimination of one or more components from blood
JP5763024B2 (ja) * 2012-09-07 2015-08-12 株式会社明治 栄養組成物
US9850278B2 (en) 2013-04-25 2017-12-26 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
CN113105559A (zh) 2013-12-12 2021-07-13 生命技术公司 增强转染的膜穿透性肽和组合物以及其使用方法
WO2020096672A1 (en) 2018-11-09 2020-05-14 The Wistar Institute Of Anatomy And Biology Use of lactoferrin for generating myeloid-derived suppressor cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2818056B2 (ja) * 1990-09-07 1998-10-30 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
AU665381B2 (en) 1992-01-23 1996-01-04 Morinaga Milk Industry Company Limited Antibacterial agent and treatment of article therewith
JP3312946B2 (ja) * 1993-03-04 2002-08-12 雪印乳業株式会社 ウイルス感染・増殖抑制剤
JP3347819B2 (ja) 1993-06-28 2002-11-20 森永乳業株式会社 抗菌性ペプチドの精製方法
JP3529423B2 (ja) 1994-04-01 2004-05-24 森永乳業株式会社 抗菌性ペプチドの製造方法
JP3738042B2 (ja) 1994-05-17 2006-01-25 森永乳業株式会社 非経口用抗腫瘍剤
JP3812957B2 (ja) 1994-08-02 2006-08-23 森永乳業株式会社 角膜損傷治療剤
JP3506274B2 (ja) 1994-09-01 2004-03-15 雪印乳業株式会社 新規ペプチドおよび免疫賦活剤
JPH08143468A (ja) 1994-11-17 1996-06-04 Morinaga Milk Ind Co Ltd 抗潰瘍剤
JP3830179B2 (ja) * 1995-07-31 2006-10-04 森永乳業株式会社 抗寄生虫剤
JPH09165342A (ja) 1995-12-14 1997-06-24 Morinaga Milk Ind Co Ltd 抗真菌剤
JP2001504447A (ja) 1996-08-12 2001-04-03 エイプラス サイエンス インベスト アーベー ラクトフェリンおよび／またはラクトフェリシンでの、感染、炎症および／または腫瘍の処置および予防
JPH1059864A (ja) * 1996-08-15 1998-03-03 Morinaga Milk Ind Co Ltd 経口がん転移抑制剤
SE9804614A0 (en) * 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof

Also Published As

Publication number Publication date
AU752640B2 (en) 2002-09-26
US7803757B2 (en) 2010-09-28
CA2333306C (en) 2011-12-06
SE9804614D0 (sv) 1998-12-29
HK1036630A1 (en) 2002-01-11
US7253143B1 (en) 2007-08-07
EP1095061B1 (de) 2007-12-19
SE9804614A0 (en) 2000-01-07
JP4488622B2 (ja) 2010-06-23
PT1095061E (pt) 2008-03-10
JP2010090162A (ja) 2010-04-22
DK1095061T3 (da) 2008-04-21
DE69937798D1 (de) 2008-01-31
ES2299253T3 (es) 2008-05-16
ATE381578T1 (de) 2008-01-15
WO2000001730A1 (en) 2000-01-13
CY1108049T1 (el) 2012-05-23
US20080299180A1 (en) 2008-12-04
AU5076099A (en) 2000-01-24
DE69937798T2 (de) 2009-04-30
NZ509622A (en) 2003-05-30
JP2002519438A (ja) 2002-07-02
CA2333306A1 (en) 2000-01-13
EP1095061A1 (de) 2001-05-02

Similar Documents

Publication Publication Date Title
Nagpal et al. Bioactive peptides derived from milk proteins and their health beneficial potentials: an update
Niaz et al. Lactoferrin (LF): A natural antimicrobial protein
Moreno-Expósito et al. Multifunctional capacity and therapeutic potential of lactoferrin
Beermann et al. Physiological properties of milk ingredients released by fermentation
CY1108049T1 (el) Πεπτιδια με βαση την αλληλουχια της ανθρωπινης λακτοφερρινης και χρηση τους
Expósito et al. Antibacterial activity of peptides and folding variants from milk proteins
El-Sayed et al. Milk bioactive peptides: antioxidant, antimicrobial and anti-diabetic activities
Latorre et al. LF immunomodulatory strategies: mastering bacterial endotoxin
Pepe et al. Potential anticarcinogenic peptides from bovine milk
Pan et al. Biological properties of lactoferrin: an overview
Kim et al. Understanding the roles of host defense peptides in immune modulation: from antimicrobial action to potential as adjuvants
US20090270309A1 (en) Use of lactoferrin fragments and hydrolysates
Jiang et al. Comparison of bioactivities of talactoferrin and lactoferrins from human and bovine milk
Saadi et al. Whey proteins as multifunctional food materials: Recent advancements in hydrolysis, separation, and peptidomimetic approaches
TW201004640A (en) Treatment of inflammatory bowel diseases with mammal beta defensins
Krunic et al. The contribution of bioactive peptides of whey to quality of food products
Jabbari et al. Antimicrobial peptides from milk proteins: a prospectus
Anusha et al. Bioactive peptides from milk
Huang et al. Critical importance of iron saturation in lactoferrin: effects on biological activity, nutritional functions, and applications
McCarthy et al. Bioactive peptides from casein and whey proteins
Lizzi et al. Lactoferrin derived peptides: mechanisms of action and their perspectives as antimicrobial and antitumoral agents
US20110053833A1 (en) Synthetic peptides and their use
Giansanti et al. Nutraceutical peptides from lactoferrin
Marnila et al. Lactoferrin for human health
Mishra et al. Potential of lactoferrin as a novel nutraceutical

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 9804614-7

Format of ref document f/p: F